Researchers at Semmelweis University analyzed how depression, smoking, obesity, sleep disorders, and other health problems are linked to difficult-to-treat rheumatoid arthritis (D2T-RA) and how this can inform treat-to-target (T2T) and individualized therapy.
Dr. John Cush RheumNow
4 months ago
Trends and Innovations in Lupus Nephritis Clinical Trials
Xu et al. from Shanghai University have written an analysis of global lupus nephritis (LN) clinical trials and call for innovation.
This systematic review of was informed by 200 interventional pharmacological trials https://t.co/fUTIMhMAis
Dr. John Cush RheumNow
4 months ago
Cross-sectional study of 339 IBD pts (64% women, median 42yrs (32–53) found osteopenia by BMD in 34%, OP in 12%. Predictors not identified by multivariable analysis. Rheum eval led to OP Rx in 7% & vitamin D in 45% https://t.co/CNs7hb9KX8 https://t.co/aoesaW1pKw
Dr. Jack Cush reviews safety of biologics and novel agents.
Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, in collaboration with Genentech, a member of the Roche Group, announced the inaugural recipients of the Lupus Research Alliance-Genentech Award on Immune Resetting Therapies for Lupus (LGA-IRT).
Dr. John Cush RheumNow
4 months ago
US Biobank (n=480K) study of mobile phone use. W/ 13.6 yrs F/U, 6082 new RA. Cell phone use incr incident RA 14% (HR: 1.14; 1.07–1.23); w/ 8% risk (HR: 1.08) if used >30 min/wk. Speakerphone use was NS. https://t.co/U7TcyoY5SS https://t.co/kqqnFXwaEi
Dr. John Cush RheumNow
4 months ago
Population cohort study of pregnancies from UK Clinical Practice Research Datalink, 5.2 million pregnancies, ~2.5 mill births. Incr risk for miscarriage in Sjögrens (aRR 1.66), C-sect in IBD (1.27), SGA in SLE (2.45), preterm birth in RA (1.53), stillbirth in SLE (1.82) & more https://t.co/IjtRTE2t78
Dr. John Cush RheumNow
4 months ago
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?
Dr. John Cush RheumNow
4 months ago
VACIMRA RCT in 249 RA pts on MTX were PCV13 vaccinated & continued or held MTX x 4wks. Best humoral responses w/ holding MTX x4wks with no clinical detriment over next 12 mos (remission, LDA, Xray outcomes) https://t.co/b6ByOYY0Fi https://t.co/XeJURKLpL8
Dr. John Cush RheumNow
4 months ago
30 yr Retrospective study of 1216 SLE hospitalizations in Barcelona - SLE flares & infections were most frequent. Hosp for infections signif. increased & in last 5yrs, exceeded Dz flares (34% vs. 26%). Younger pts had more flare hosp; older more infx hosp. Over time infx have https://t.co/TkUiXaoL1R
The Wall St. Journal has published a perspective on nurse practitioners (NP) and their very promising careers.
Dr. John Cush RheumNow
4 months ago
RHEUM SURVEY> Per 2024 EULAR Guidelines, an active RA pt on MTX who fails a 1st TNFi, should next change to ?
Dr. John Cush RheumNow
4 months ago
Quiz Talk (5.22.2026)
Dr. Jack Cush talks of birthdays, quizzes, and journal articles this week on the podcast.
https://t.co/LwX0XxgPhn https://t.co/4uVTQo6NLG
Dr. John Cush RheumNow
4 months ago
BE BOLD Week 16 data - Bimekizumab vs. Risankizumab in PsA
UCB has released the Week 16 results from BE BOLD trial that will be presented at EULAR 2026 in London on Saturday, June 6. This head-to-head trial demonstrates that at week 16, bimekizumab (BKZ) yielded superior ACR50 https://t.co/VVBaNdWIuQ
